Back to Search
Start Over
Immunomodulation by chemotherapeutic agents against Leishmaniasis
- Source :
- International Immunopharmacology. 11:1668-1679
- Publication Year :
- 2011
- Publisher :
- Elsevier BV, 2011.
-
Abstract
- Leishmaniasis is caused by protozoan parasites of the genus Leishmania and causes a wide spectrum of clinical manifestations ranging from self-healing cutaneous lesions to the fatal visceral form. The use of pentavalent antimony, the mainstay of therapy of Leishmaniasis is now limited by its toxicity and alarming increase in unresponsiveness, especially in the Indian subcontinent. Furthermore, other anti-leishmanial drugs are unaffordable in many affected countries and as vaccination based approaches have not yet proved to be effective, chemotherapy remains the only alternative, emphasizing the need for identifying novel drug targets. In this review, we have described the different host immune signaling pathways that could be considered as potential drug targets for Leishmania chemotherapy.
- Subjects :
- Drug
Immune signaling
Neutrophils
medicine.medical_treatment
media_common.quotation_subject
Immunology
Antiprotozoal Agents
Biology
Genus: Leishmania
Host-Parasite Interactions
Immunomodulation
medicine
Animals
Humans
Immunology and Allergy
Lymphocytes
Leishmaniasis
media_common
Leishmania
Pharmacology
Chemotherapy
Macrophages
Dendritic Cells
medicine.disease
biology.organism_classification
Vaccination
Indian subcontinent
Subjects
Details
- ISSN :
- 15675769
- Volume :
- 11
- Database :
- OpenAIRE
- Journal :
- International Immunopharmacology
- Accession number :
- edsair.doi.dedup.....57481128292ae921c6915b67225c8f4a